QTRX
NASDAQQuanterix Corporation
Price$3.02-0.21 (-6.35%)
01:30 PM02:45 PM
News · 26 weeks70-31%
2025-12-142026-06-07
Mix3590d
- Insider13(37%)
- Other10(29%)
- SEC Filings7(20%)
- Earnings3(9%)
- Leadership2(6%)
Latest news
25 items- SECQuanterix Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Quanterix Corp (0001503274) (Filer)
- PRQuanterix Announces Appointment of Jason Faessler as Chief Financial OfficerQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's strategic growth plans in the coming years. "We are thrilled to welcome Jason to the Quanterix leadership team," said Everett Cunningham, Chief Executive Officer of Quanterix. "His extensive track record within life science organization
- PRQuanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of DiagnosticsStrategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante
- PRQuanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Company and its strategic priorities. The Company is also scheduling one-on-one investor meetings at the event. Webcast Information The live webcast presentation can be accessed from the Investor Relations section of the company's webs
- INSIDERChief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.27% to 33,795 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- SECQuanterix Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Quanterix Corp (0001503274) (Filer)
- PRQuanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the "Inducement Grant") was made to Anthony Catalano in connection with the commencement of his employment as the Chief Operating Officer of the Company. The Inducement Grant consists of restricted stock units ("RSUs") covering 141,330 shares of Quanterix common stock. The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Catalano's continued employment with the Company or one of its subsidiaries throu
- INSIDERChief Financial Officer Sriram Vandana converted options into 1,833 shares and covered exercise/tax liability with 548 shares, increasing direct ownership by 4% to 29,998 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERChief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 33,704 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quanterix CorporationSCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quanterix CorporationSCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)
- SECQuanterix Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Quanterix Corp (0001503274) (Filer)
- PRQuanterix Announces Planned Transition of Chief Financial OfficerQuanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO") will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition. "Vandana has made impactful contributions to Quanterix since joining the Company in 2023," stated Everett Cunningham, President and Chief Executive Officer of Quanterix. "Her leadership and contributions have been instrumental in the ongoing evolution of the company and have helped create a strong foundation
- SECSEC Form DEFA14A filed by Quanterix CorporationDEFA14A - Quanterix Corp (0001503274) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quanterix CorporationSCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)
- SECSEC Form 10-Q filed by Quanterix Corporation10-Q - Quanterix Corp (0001503274) (Filer)
- SECQuanterix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Quanterix Corp (0001503274) (Filer)
- PRQuanterix Releases Financial Results for the First Quarter of 2026Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition," said Everett Cunningham, President & CEO of Quanterix. "As part of this process, we are focusing our
- PRLucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical WorkflowsAgreement supports the identification of patients eligible for Alzheimer's disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus' clinical ordering platform Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing, with the LucentAD® Co
- INSIDERChief Operating Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.28% to 32,613 units (SEC Form 4)4 - Quanterix Corp (0001503274) (Issuer)
- PRQuanterix To Report First Quarter 2026 Financial Results on May 6, 2026Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. In conjunction with this announcement, the Company will host a conference call on May 6, 2026, at 4:30 PM ET. The dial-in number for USA & Canada
- SECSEC Form DEF 14A filed by Quanterix CorporationDEF 14A - Quanterix Corp (0001503274) (Filer)
- INSIDERSEC Form 4 filed by Miller Michael Francis4 - Quanterix Corp (0001503274) (Issuer)
- INSIDERSEC Form 4 filed by Sriram Vandana4 - Quanterix Corp (0001503274) (Issuer)
- PRAidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical OncologyNovel Assay, Developed on Akoya PhenoImager HT Platform with Opal Chemistry, Becomes First to Predict Both Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer PreludeDx® and Quanterix Corporation (NASDAQ:QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone receptor-positive, HER2-negative invasive breast cancer
QTRX FAQ
7 questionsWhat does Quanterix Corporation do?
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the...Where does QTRX stock trade?
Quanterix Corporation (QTRX) is listed on NASDAQ.What sector and industry is QTRX in?
Quanterix Corporation operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Quanterix Corporation go public?
Quanterix Corporation (QTRX) completed its IPO in 2017.What are analysts saying about QTRX?
Quanterix Corporation has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Hold with a $500.00 price target on 2025-08-11.What companies are similar to QTRX?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare QTRX side-by-side with any of them on Quantisnow.How can I track QTRX on Quantisnow?
Quantisnow aggregates Quanterix Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QTRX to receive live email and push alerts on every new disclosure.